Form 8-K

8-K — Turn Therapeutics Inc.

Accession: 0001213900-26-064405

Filed: 2026-06-03

Period: 2026-06-03

CIK: 0002023016

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0293128-8k_turn.htm (Primary)

EX-99.1 — INVESTOR PRESENTATION, DATED JUNE 3, 2026 (ea029312801ex99-1.htm)

GRAPHIC (ea029312801_ex99-1img1.jpg)

GRAPHIC (ea029312801_ex99-1img2.jpg)

GRAPHIC (ea029312801_ex99-1img3.jpg)

GRAPHIC (ea029312801_ex99-1img4.jpg)

GRAPHIC (ea029312801_ex99-1img5.jpg)

GRAPHIC (ea029312801_ex99-1img6.jpg)

GRAPHIC (ea029312801_ex99-1img7.jpg)

GRAPHIC (ea029312801_ex99-1img8.jpg)

GRAPHIC (ea029312801_ex99-1img9.jpg)

GRAPHIC (ea029312801_ex99-1img10.jpg)

GRAPHIC (ea029312801_ex99-1img11.jpg)

GRAPHIC (ea029312801_ex99-1img12.jpg)

GRAPHIC (ea029312801_ex99-1img13.jpg)

GRAPHIC (ea029312801_ex99-1img14.jpg)

GRAPHIC (ea029312801_ex99-1img15.jpg)

GRAPHIC (ea029312801_ex99-1img16.jpg)

GRAPHIC (ea029312801_ex99-1img17.jpg)

GRAPHIC (ea029312801_ex99-1img18.jpg)

GRAPHIC (ea029312801_ex99-1img19.jpg)

GRAPHIC (ea029312801_ex99-1img20.jpg)

GRAPHIC (ea029312801_ex99-1img21.jpg)

GRAPHIC (ea029312801_ex99-1img22.jpg)

GRAPHIC (ea029312801_ex99-1img23.jpg)

GRAPHIC (ea029312801_ex99-1img24.jpg)

GRAPHIC (ea029312801_ex99-1img25.jpg)

GRAPHIC (ea029312801_ex99-1img26.jpg)

GRAPHIC (ea029312801_ex99-1img27.jpg)

GRAPHIC (ea029312801_ex99-1img28.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0293128-8k_turn.htm · Sequence: 1

false

0002023016

2026-06-03

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

June 3, 2026

TURN THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware

001-42875

32-0456090

(State or other jurisdiction of

incorporation)

(Commission File Number)

(IRS Employer

Identification Number)

250 N. Westlake Blvd., Westlake Village, California

91362

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (818) 564-4011

N/A

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

Common Stock, par value $0.0001 per share

TTRX

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure.

On June 1, 2026, Turn Therapeutics

Inc. released an updated investor presentation (the “Investor Presentation”). A copy of the Investor Presentation is furnished

as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01

of this Current Report on Form 8-K and the Investor Presentation furnished as Exhibit 99.1 hereto shall not be deemed “filed”

for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to

the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended,

or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Investor Presentation, dated June 3, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

TURN THERAPEUTICS INC.

Date: June 3, 2026

By:

/s/ Bradley Burnam

Name:

Bradley Burnam

Title:

Chief Executive Officer

EX-99.1 — INVESTOR PRESENTATION, DATED JUNE 3, 2026

EX-99.1

Filename: ea029312801ex99-1.htm · Sequence: 2

Exhibit

99.1

2026 Jefferies Global Healthcare Conference June 2026

2 Disclaimer Except for historical information set forth herein, the matters set forth in this presentation contain forward - looking statement s within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward - looking statements may be identified by words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates,” “predicts," "potential" or "continue," the negative of these terms and other comparable terminology. We cannot guarantee futu re results, level of activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward - looking stateme nts. We are under no duty to update any of these forward - looking statements after the date of this presentation to conform our prior statements to actual results or revised expectations. These statements are based upon the current beliefs and expectations of Turn Therapeutics' management and are subject to sign ifi cant risks and uncertainties. By their nature, forward - looking statements involve risks and uncertainties because they depend on circumstances that may or may not occur in the future. If u nde rlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially. Risks include: industry competition; economic factors; regulatory challenges; uncertainties in clinical development and obtai nin g regulatory approvals; no guarantees that pipeline products will prove commercially successful; reliance on third - party partnerships and manufacturers; dependence on patent protections for PermaFusion ®; and ability to access adequate capital. Although these statements are based on assumptions we believe are reasonable, we caution that forward - looking statements are not guarantees of future performance and you should not place undue reliance on them. Turn Therapeutics undertakes no obligation to publicly update any forward - looking statement, whether as a result of new information, future events or otherwise. Additional factors can be found in the company's SEC filings available at www.sec.gov. This presentation includes market and industry data and forecasts that the Company has derived from independent consultant re por ts, publicly available information, various industry publications, other published industry sources, and its internal data and estimates. Independent consultant reports, industry publications and other published industry sources generally indicate that the information contained therein was obtained from sources believed to be reliable. Although the Company believes that these thi rd - party sources are reliable, it does not guarantee the accuracy or completeness of this information, and the Company has not independently verified this information. The Company's internal dat a a nd estimates are based upon information obtained from trade and business organizations and other contacts in the markets in which the Company operates and management's understanding of indu str y conditions. Although the Company believes that such information is reliable, it has not had this information verified by any independent sources. In addition, the information co nta ined in this presentation is as of the date hereof (except where otherwise indicated), and the Company has no obligation to update such information, including in the event that such information become s i naccurate or if estimates change. Subsequent materials may be provided by or on behalf of the Company in its discretion and such information may supplement, modify or supersede the inform ati on in these materials. Neither the Company, nor any of its respective affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any l oss or damage howsoever arising from any use of these materials or their contents or otherwise arising in connection with these materials. This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the propert y o f their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, SM or sy mbo ls, but the Company will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights.

3 API in Liquid Solvent Patented Multi - Step Mixing Process w/out Emulsifier Petro / Oil Carrier A transformative delivery platform enabling stable, emulsifier - free dispersion of active ingredients in oil - based carriers for superior penetration by APIs • Multi - patented, proprietary process • API - agnostic drug delivery platform designed for continued innovation • Suspended, non - diluted nanodroplets embedded within oil - based carrier deliver active ingredients through skin, nails, and mucous membranes • Compatible with any liquid or liquid - soluble API, including live payloads (i .e. viruses/vectors) PermaFusion : API Agnostic Delivery Platform 3 1.3 Micron Active ingredient nanodroplets suspended within petrolatum matrix

Turn Therapeutics is a biotechnology company developing first - in - class, precision, non - systemic immunomodulation therapies that target IL - 36 and key downstream cytokines to address high - unmet - need inflammatory diseases, with an initial focus on moderate to severe AD. 1. In other FDA cleared indications (or as a management tool for chronic wound care) IL - 36/IL - 31 Inhibitor – GX - 03 Robust IP including issued composition and method patents, supporting durable commercial exclusivity Novel MOA employs precision immunomodulation to prevent unnecessary immune activation and systemic uptake Executive Summary 4 ZERO reported adverse events 200,000+ patients have received GX - 03 ¹ FDA clearances with non - cytotoxic, non - sensitizing and non - irritating claims Phas e 2 RCT trial underway for moderate to severe AD, topline results expected mid - 2026

5 Medical Devices FDA - cleared antimicrobial surgical gauze out - licensed Sterile collagen powder out - licensed for $70M+ milestones Turn Tx Pipeline PHASE 3 PHASE 2 PHASE I PRECLINICAL Moderate - to - Severe Atopic Dermatitis (AD) GX - 03 IL - 36, IL - 36, IL - 31 and IL - 4 inhibitor Non - systemic and non - steroid potentially best - in - class topical Onychomycosis (Toenail Fungus) Undisclosed Dermatological Candidate

6 GX - 03 for AD IL - 31 IL - 4 IL - 36

7 The Chronic Inflammatory ‘Loop’ TH2 IL - 4, IL - 13, IL - 31 IL - 31 Chronic AD Cycle IL - 31 Drives Itch & Scratch Skin Barrier Disruption Skin barrier disruption results in release of IL - 36 IL - 36 initiates TH2 signaling with IL - 4, IL - 13, and IL - 31 release IL - 31 release drives itch which leads to further disruption of the skin barrier and restarts loop 7 IL - 36 Th2 Immune Response

8 Stop the ‘Loop’ GX - 03 Inhibition 8 GX - 03 suppresses IL - 36 release via targeted modulation of the epithelial microenvironment, blunting Th2 response GX - 03 suppresses Il - 31 signaling, blunting itch/scratch signal and continued barrier disruption IL - 36 and IL - 31 Inhibition GX - 03 targets key upstream and downstream cytokines to stop the chronic inflammatory ‘loop’

9 Phase 2 Adaptive Study Design Design: • Double - blind • 1:1 Randomized • Vehicle Controlled • Week 4 and Week 8 Endpoints • IDMC Governed Adaptive Design 9 Initial Trial Design – Stage 1 Endpoints & Exploratory Measurements: • vIGA 0 or 1 and ≥ 2 points drop at W4 & W8 • % change in EASI at W4 & W8 • PP - NRS (itch) ≥4 points drop at W4 & W8 • Patient Oriented Eczema Measure (POEM) at W4 & W8 Population: • Moderate - Severe Atopic Dermatitis based on EASI (>7) or IGA of 3/4 • Age: 18 – 80 • N = 120 – 200 (adaptive) 1. A Study to Assess Efficacy of GX - 03 in Moderate to Severe AD 2026 2025 Jul 2025 First patient enrolled Q2 2026 Adaptive interim analysis Mid - 2026 Topline data readout N = 50 Adaptive design Optimized Stage 2 of Trial

FAS GX-03 Vehicle N = 50 N = 27 N = 23 Baseline EASI Mean 8.19 10.16 5.87 Range 1.2 - 43.1 1.2 - 43.1 1.4 - 19.5 Standard Deviation 8.85 10.93 4.77 Baseline EASI ≥ 21, n (%age) 4 (8%) 4 (15%) 0 (0%) Baseline IGA [0-4 score] Mean 3.12 3.19 3.04 Range 2 - 4 3 - 4 2 - 4 Standard Deviation 0.39 0.40 0.37 Baseline IGA = 4, n (%age) 7 (14%) 5 (19%) 2 (9%) PP-NRS (itch) [0-10 score] Mean 6.36 6.07 6.7 Range 0 - 10 0 - 10 3 - 10 Standard Deviation 2.37 2.60 2.08 Baseline ≥ 6, n (%age) 35 (70%) 18 (67%) 17 (74%) Interim Analysis Population - Baseline Characteristics 10

Interim Analysis – Summary Results of Stage 1 Endpoints and Commonly Tracked AD Measurements 11 GX-03 Vehicle GX-03 Vehicle At Week 4 At Week 4 Difference At Week 8 At Week 8 Difference Change EASI Mean % Reduction 79.43% 50.55% 28.88% 77.22% 62.70% 14.52% EASI-50 (%pts) 92.6% 65.2% 27.39% 81.5% 69.6% 11.93% EASI-75 (%pts) 70.4% 56.5% 13.85% 66.7% 56.5% 10.20% EASI-90 (%pts) 44.4% 30.4% 14.01% 51.9% 34.8% 17.12% EASI-100 (%pts) 18.5% 4.3% 14.15% 40.7% 17.4% 23.31% IGA 0 or 1 (% pts) 59.3% 34.8% 24.50% 70.4% 65.2% 5.20% PP-NRS 0 or 1 (% pts) 55.6% 39.1% 16.43% 63.0% 60.9% 2.09% Week 4 Week 8

Interim Analysis - EASI Percentage Reduction Over Time 12 EASI Change from Baseline (%) 79.43% 77.22% 50.55% 62.70

Interim Analysis - EASI Responder Rates 13 % P atients achieving response Deepening of response observed in patients with higher baseline EASI

Select Patients With High Baseline Disease Burden 14 34.8 0.2 0.0 3 1 0 ▼ EASI - 100 IGA = 0 12.8 3.6 0.0 3 2 0 ▼ EASI - 100 IGA = 0 16.4 1.6 0.4 4 1 1 ▼ EASI - 90 IGA = 1 3 2 2 13.2 4.8 2.4 4 4 3 19.5 14.4 12.8

Interim Analysis - Safety Summary 15 * Subject reported a mild warming sensation that was described as pleasant. ** Subject reported a common cold which was determined by PI to be unrelated to study. “ Favorable safety and tolerability profile is encouraging and supports the potential for GX - 03 to become an important first - line treatment option ” Dr. Stephen Bresnick, MD GX-03 Vehicle N = 27 N = 23 Subjects with AE, n 1* 1** Severe (Grade ≥ 2) 0 0 Serious AEs 0 0 AEs leading to study drug discontinuation 0 0

GX - 03 Interim Analysis Findings Compared to Pivotal Trials for Approved Topicals ** 16 * * * * * * * Product approved for mild - to - moderate Atopic Dermatitis ** For illustrative purposes only: Not a head - to - head analysis. Comparisons of data should be interpreted with caution due to di fferences in compounds, study designs, subject characteristics, and other factors that may limit direct comparability.

17 Trial Optimization Strategy – Stage 2 17 Endpoint Strategy : Interim findings suggest GX - 03 activity may be most visible and clinically meaningful in earlier efficacy measures evaluating reduction in inflammatory burden . Based on these observations and advisor feedback, Stage 2 is expected to emphasize Week 4 endpoints, with EASI - 75 emerging as a leading candidate due to its clinical relevance, regulatory precedent, and alignment with the observed product profile . Anticipated Inclusion Criteria : Baseline EASI of ≥ 7 , BSA of ≥ 8 % , IGA of 3 or 4 and PP - NRS ≥ 4 . Enrollment Status : Ongoing enrollment nearing N= 100 . Sample size adaptation TBD pending consultation with IDMC . Type B Meeting Package in Progress : Preparation of a Type B meeting package is underway . Discussions are expected to focus on opportunities to optimize the GX - 03 development pathway, leveraging the formula’s continuing favorable safety profile and observed rapid onset of activity .

18 GX - 03 Market Opportunity GX - 03 - Commercial Opportunity 02 03 Topical JAK / PDE4 With or without steroids due to moderate efficacy Side effects and black - box warnings Biologics Systemic burden Immunosuppression and site reactions 01 Topical Steroids Quick relief Consistent use can cause necrosis Potential for Safe, Rapid Disease Control Without Systemic Exposure

19 (Toenail Fungus) Phase 3 Ready GX - 03 for Onychomycosis

20 Study Results • Visible evidence of Beau’s line development, clear nail plate • 70% efficacy (approx .) with once - daily application • 85% efficacy (approx .) with BID application • No adverse events reported during the study Study Design • N ~ 100 • GX - 03 applied once daily or BID application • No debridement or occlusive dressings required Phase 2 Equivalent Study “Novel Approach to Polymicrobial Nail Infection” R. Dan Davis, DPM

21 1. pubmed.ncbi.nlm.nih.gov GX - 03 successfully penetrated nails and eliminated fungal pathogens in the standard model In the same in - vivo model, GX - 03 successfully penetrated the nail, REDUCING FUNGAL BURDEN BY 12 % - 18% with just two weeks of application. ¹ Lipid - based delivery enables passive diffusion of API through lipid bilayers. Currently approved topical onychomycosis products have failed to penetrate the nail and eliminate fungal pathogens leading to lower efficacy: 8.9% 6.5% 17.8% Current Topicals for Onychomycosis 100 80 60 40 20 0 Group 3 (infected + GX - 03) Group 2 (infected control) Group 1 (non - infected control)

22 2026 Phase 3 Ready 2029 Planned Launch GX - 03 Path to Market 3 High Unmet Needs • Effective therapies as current topical treatments are only 6 - 18% effective • Patent cliff for current onychomycosis treatments in 2026 Onychomycosis TAM & Prevalence 3. Subject to successful completion of each phase and capital availability. Today by 2030 $1.96B $2.8B 7.55% CAGR US Market Size 2 2027 Phase 3 Initiation 22 47.6M patients suffer from onychomycosis in U.S. 1 in 7 people globally suffers from onychomycosis 1 Only 15% of the affected population seeks treatment due to lack of awareness, limited efficacy and hepatoxicity of available therapeutics 1. www.cdc.gov 2. Precedence Research - Onycho Treatment market .com

23 Our Science

IL - 36 Auto - immune Blistering Diseases Psoriasis Actinic Keratosis Hidradenitis Suppurativa IL - 31 Prurigo Nodularis Bullous Pemphigoid Chronic Pruritus GX - 03 Broader Opportunities in Dermatology and I&I Diseases 24

25 Corporate & Financial Highlights

26 Financial & IP Highlights $18M Cash burned since inception $55 - 60M Expected R&D spend for Phase 3 trials on both indications ~$250K/mo. Expected G&A burn as a public co. $10 - 13M Expected G&A spend to thru 2028 $ 29M Total money raised since inception (2015) $11M Cash Balances As of March 31, 2026 ~30M Common Shares Outstanding As of March 31, 2026 Cash Runway into Q1’2027 Additional debt/equity tranches available under existing facilities Coverage Through 2037 Various applications pending to extend coverage 17 Issued Patents Various additional applications pending Extensive Patent Families Various patent families for composition and/or methods around API

27 Board Members Advisors & KOLs Arthur Golden, JD Andrew Gengos Kent Kester, MD Martin Dewhurst Senior Counsel, Davis Polk & Wardwell Former CFO Terns Pharmaceuticals Executive Director, Vaccine Research and Development at CEPI McKinsey Veteran Senior Advisor at PJT Partners Bradley Burnam Dr. Stephen Hahn, MD Dr. Neil Ghodadra , MD Zuraiz Chaudhary CEO, Chairman & Founder Clinical and Regulatory Lead Chief Medical Officer Chief Accounting Officer Key Management Stephen Bresnick, MD Board Certified Plastic Surgeon Dr. Stephen Bresnick is a board - certified surgeon in skin health and immunology - related fields, has two doctorate degrees, and is an esteemed research publisher. Dr. Bresnick is an advisor and KOL for Turn’s Atopic Dermatitis program. Dr. R. Daniel Davis, DPM Former President, CPMA & APMA Board of Trustee Dr. Davis is board Certified Foot and Ankle Surgeon and has been in practice for over 30 years. Dr. Dan Davis is an advisor and KOL for Turn’s onychomycosis program. Dr. Robert Redfield Former Director, CDC Dr. Redfield is a nationally recognized virologist and public health leader who served as Director of the CDC. As Senior Advisor of Health Policy and Regulatory Affairs at Turn. Management & Board Sasha Damouni Ellis Corporate Communications & IR Arthur Golden, JD

Investors@turntherapeutics.com 250 N. Westlake Blvd, #210 Westlake Village, CA 91362 Thank You.

GRAPHIC

Filename: ea029312801_ex99-1img1.jpg · Sequence: 3

Binary file (715946 bytes)

Download ea029312801_ex99-1img1.jpg

GRAPHIC

Filename: ea029312801_ex99-1img2.jpg · Sequence: 4

Binary file (1667966 bytes)

Download ea029312801_ex99-1img2.jpg

GRAPHIC

Filename: ea029312801_ex99-1img3.jpg · Sequence: 5

Binary file (1074245 bytes)

Download ea029312801_ex99-1img3.jpg

GRAPHIC

Filename: ea029312801_ex99-1img4.jpg · Sequence: 6

Binary file (890990 bytes)

Download ea029312801_ex99-1img4.jpg

GRAPHIC

Filename: ea029312801_ex99-1img5.jpg · Sequence: 7

Binary file (506587 bytes)

Download ea029312801_ex99-1img5.jpg

GRAPHIC

Filename: ea029312801_ex99-1img6.jpg · Sequence: 8

Binary file (540060 bytes)

Download ea029312801_ex99-1img6.jpg

GRAPHIC

Filename: ea029312801_ex99-1img7.jpg · Sequence: 9

Binary file (688919 bytes)

Download ea029312801_ex99-1img7.jpg

GRAPHIC

Filename: ea029312801_ex99-1img8.jpg · Sequence: 10

Binary file (622434 bytes)

Download ea029312801_ex99-1img8.jpg

GRAPHIC

Filename: ea029312801_ex99-1img9.jpg · Sequence: 11

Binary file (641888 bytes)

Download ea029312801_ex99-1img9.jpg

GRAPHIC

Filename: ea029312801_ex99-1img10.jpg · Sequence: 12

Binary file (544506 bytes)

Download ea029312801_ex99-1img10.jpg

GRAPHIC

Filename: ea029312801_ex99-1img11.jpg · Sequence: 13

Binary file (523164 bytes)

Download ea029312801_ex99-1img11.jpg

GRAPHIC

Filename: ea029312801_ex99-1img12.jpg · Sequence: 14

Binary file (320464 bytes)

Download ea029312801_ex99-1img12.jpg

GRAPHIC

Filename: ea029312801_ex99-1img13.jpg · Sequence: 15

Binary file (341046 bytes)

Download ea029312801_ex99-1img13.jpg

GRAPHIC

Filename: ea029312801_ex99-1img14.jpg · Sequence: 16

Binary file (465861 bytes)

Download ea029312801_ex99-1img14.jpg

GRAPHIC

Filename: ea029312801_ex99-1img15.jpg · Sequence: 17

Binary file (526692 bytes)

Download ea029312801_ex99-1img15.jpg

GRAPHIC

Filename: ea029312801_ex99-1img16.jpg · Sequence: 18

Binary file (484743 bytes)

Download ea029312801_ex99-1img16.jpg

GRAPHIC

Filename: ea029312801_ex99-1img17.jpg · Sequence: 19

Binary file (987108 bytes)

Download ea029312801_ex99-1img17.jpg

GRAPHIC

Filename: ea029312801_ex99-1img18.jpg · Sequence: 20

Binary file (635925 bytes)

Download ea029312801_ex99-1img18.jpg

GRAPHIC

Filename: ea029312801_ex99-1img19.jpg · Sequence: 21

Binary file (348466 bytes)

Download ea029312801_ex99-1img19.jpg

GRAPHIC

Filename: ea029312801_ex99-1img20.jpg · Sequence: 22

Binary file (776547 bytes)

Download ea029312801_ex99-1img20.jpg

GRAPHIC

Filename: ea029312801_ex99-1img21.jpg · Sequence: 23

Binary file (816782 bytes)

Download ea029312801_ex99-1img21.jpg

GRAPHIC

Filename: ea029312801_ex99-1img22.jpg · Sequence: 24

Binary file (680162 bytes)

Download ea029312801_ex99-1img22.jpg

GRAPHIC

Filename: ea029312801_ex99-1img23.jpg · Sequence: 25

Binary file (555306 bytes)

Download ea029312801_ex99-1img23.jpg

GRAPHIC

Filename: ea029312801_ex99-1img24.jpg · Sequence: 26

Binary file (671381 bytes)

Download ea029312801_ex99-1img24.jpg

GRAPHIC

Filename: ea029312801_ex99-1img25.jpg · Sequence: 27

Binary file (365921 bytes)

Download ea029312801_ex99-1img25.jpg

GRAPHIC

Filename: ea029312801_ex99-1img26.jpg · Sequence: 28

Binary file (810183 bytes)

Download ea029312801_ex99-1img26.jpg

GRAPHIC

Filename: ea029312801_ex99-1img27.jpg · Sequence: 29

Binary file (905099 bytes)

Download ea029312801_ex99-1img27.jpg

GRAPHIC

Filename: ea029312801_ex99-1img28.jpg · Sequence: 30

Binary file (714936 bytes)

Download ea029312801_ex99-1img28.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 35

v3.26.1

Cover

Jun. 03, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 03, 2026

Entity File Number

001-42875

Entity Registrant Name

TURN THERAPEUTICS INC.

Entity Central Index Key

0002023016

Entity Tax Identification Number

32-0456090

Entity Incorporation, State or Country Code

Entity Address, Address Line One

250 N. Westlake Blvd.

Entity Address, City or Town

Westlake Village

Entity Address, State or Province

Entity Address, Postal Zip Code

91362

City Area Code

818

Local Phone Number

564-4011

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

TTRX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration